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Defining Transplantation and Listing Benefit in
Patients with Chronic Obstructive Pulmonary Disease
Many chronic lung diseases demonstrate a progressive course
with severe pulmonary dysfunction heralding high short-term
mortality. Alternatively, patients with advanced chronic ob-
structive pulmonary disease (COPD) may suffer for years with
significant symptoms, making it difficult to discriminate severely
affected patients with COPD who have a high short-term risk of
death from those with lower risk. Accordingly, it is challenging
to appropriately time listing and performance of lung trans-
plantation, which has its own risks, to significantly prolong life
in these patients. In 2006, 31% of lung transplants in the United
States were for COPD, and 371 patients with COPD (36% of
those on a waitlist) were left waiting for a lung allograft (1, 2).
The decision when to list and transplant patients with COPD
affects organ utilization and therefore all lung transplant
candidates.
Thabut and colleagues (3) provide important insights in this
issue of the Journal (pp. 1156–1163). They develop models based
on individual risk factors to predict median survival with and
without transplant for patients with COPD. They then simulate
these along with organ offer times to estimate survival gains or
losses from time of listing. Although some have suggested that
risk with transplantation always exceeds risk without trans-
plantation for COPD (4, 5), Thabut and colleagues argue
that listing for lung transplantation prolongs life for approxi-
mately 50% of patients under a waiting time–based allocation
system.
Proper interpretation of Thabut and colleagues’ results re-
quires careful consideration of their definition of benefit. These
investigators address a two-part question: If waitlisted under the
former waiting time–based allocation system in the United
States, would a patient with COPD (1) live until offered a lung
allograft and (2) upon transplantation, have a longer, shorter, or
similar survival than if never waitlisted? If a patient dies during
the simulated wait time, then listing was futile. If a patient sur-
vives long enough to be transplanted in the simulation, overall
survival may be better, worse, or no different than the natural
history of that individual’s disease.
Patient 2 in Figure E4 of the online supplement conceptu-
alizes this idea. This patient has an estimated 2-year waitlist
survival time but a 3-year waiting time. Their algorithm therefore
assigns a benefit of zero, because Patient 2 did not survive long
enough to be impacted positively or negatively by transplant. If,
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however, this same patient had been transplanted a few days
after listing, he would have lived 1 year post-transplant, but lost
a year of life overall. Therefore, Thabut and colleagues’
ascribed ‘‘transplant benefit’’ may more accurately be described
as ‘‘listing benefit,’’ because some simulated patients don’t
survive to see a transplant benefit (or risk).
Although calculated using many common variables, Thabut
and coworkers’ estimated listing benefit should not be confused
with transplant benefit, as defined in the Lung Allocation Score
(LAS) (6), which is used to prioritize patients for lung trans-
plantation in the United States. First, as opposed to median
survival gains due to listing, the LAS estimates patient-days
gained or lost over the year after a lung transplant. In contrast
to Thabut and colleagues’ simulations, the LAS does not
consider wait times, the probability of surviving until an offer,
or outcomes after 1 year, but it does estimate transplant benefit
for all listed patients. LAS benefit projections recorded for
patients with emphysema/COPD transplanted from May 2005
to June 2007 had 12.7% of transplanted patients with positive
1-year transplant benefit and, using a longer projection, 22.0%
with positive 3-year benefit (7).
Another difference between Thabut and colleagues’ listing
benefit and LAS transplant benefit centers on those simulated
patients who live long enough to get transplanted in the model.
Because better waitlist survival is likely correlated with both living
until being offered an allograft and post-transplant outcomes,
Thabut and coworkers’ simulation results may be weighted toward
healthier patients. As fewer patients with poor waitlist survival get
the opportunity for transplant in the simulation, the listing benefit
calculations may be less applicable to patients ordered by LAS.
Sicker patients actually get a better chance at allocation under the
LAS system, potentially resulting in worse post-transplant out-
comes, although this is yet to be determined.
Some take a broader view of benefit than is reflected in the
relatively simplistic estimates of both Thabut and colleagues
and the LAS. Although prolonging survival is an important
goal, impact on quality of life is another crucial consideration.
Many patients would gladly trade years of life burdened with
severe COPD for the same or smaller number of years of an
active post-transplant lifestyle. Although controversial, our
fiduciary responsibility to patients may warrant listing and
transplanting such individuals despite a lack of survival benefit.
Thabut and coworkers observed that double-lung transplan-
tation had a lower estimated risk than single-lung transplanta-
tion. The inclusion of procedure type in modeling post-transplant
outcomes poses some difficulty. Often, a patient with COPD may
be eligible for either a single- or double-lung transplant and
accept whichever is offered first. At listing, it may be unclear
which procedure the patient will eventually receive, making it
impossible to divine what the listing benefit will actually be. Of
course, whether procedure choice itself confers a survival benefit
is controversial and will unlikely be answered in an entirely
unbiased fashion by nonrandomized studies.
Thabut and colleagues aim to help a clinician decide if a
patient with COPD should be listed for transplant, based on the
historical wait times and experience in the United Network for
Organ Sharing. As advised by the authors, this model should
not be used clinically until externally validated. The dramatic
alteration in wait times and organ allocation from the LAS
score might affect the accuracy of this system based on the older
system and purely on time waiting. In addition, patients with
COPD who did not necessarily need immediate transplantation
were often waitlisted to accrue time under the old system. This
means that patients whom we might consider to waitlist for
transplant in 2008 may be an entirely different subset (or at a
different point in their disease course) from those used to derive
both Thabut and colleagues’ models and the LAS. Therefore,
we await further studies in the United States and around the
world to help decide when ‘‘to transplant or not to transplant’’
patients with COPD.
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Predicting Tuberculosis
Does the IGRA Tell the Tale?
The tuberculin skin test (TST) has been used to diagnose
infection with Mycobacterium tuberculosis for close to 100 years.
This longevity reflects the TST’s low cost and ease of admin-
istration, as well as the numerous longitudinal studies correlating
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